BIOSIMILAR DRUGS
TODAY'S HEADLINES
FDA's recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen's top-selling Enbrel for rheumatoid arthritis, plaque psoriasis and other inflammatory conditions, stands to save the US healthcare system millions of dollars. Here's how |
|
FDA recently granted breakthrough therapy designation for esketamine, an investigational medication to treat major depressive disorder with imminent risk for suicide. How it's unique
|
CONTINUING PHARMACY EDUCATION
This month's CE activity, "The role of the community pharmacy team in assisting patients receiving oral anticancer medications," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians about oral anticancer medications.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
|
EDITOR'S PICK
Despite FDA's approval of infliximab-dyyb (Inflectra), a biosimilar to Remicade for rheumatoid arthritis, Crohn's disease and other conditions in April, FDA's approval pace for biosimilars is too slow, according to a pharmacy benefit manager (PBM). Read more
|
|
|
